Abnormal mitotic activity underlies the pathology of a number of human diseases, most notably cancer, and has motivated the search for more specific and less toxic inhibitors of the mitotic process. In this chapter, I review the clinical experience with one group of inhibitors that target mitotic kinesins. I will discuss the results of phase I and II trials with these drugs and place the results of these trials in a context to explain how they can be utilized in future human studies.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)